Vaxxas is commercializing a novel vaccination technology that enhances the performance of existing and next-generation vaccines.

Needle-free Technology

The core of Vaxxas technology platform is a High Density Microarray Patch (HD-MAP). Vaxxas' HD-MAP is readily fabricated by injection molding to produce small patches each with thousands of very short (~0.25mm) microprojections.

Vaxxas has developed novel technologies that enable vaccines to be applied to the tips of the microprojections under sterile conditions. The HD-MAP delivers the vaccine on its microprojections efficiently to the high density populations of immune cells directly beneath the surface of the skin. The microprojections also trigger natural immuno-cellular alarms that cause vaccine components to be rapidly trafficked to lymph nodes eliciting a robust immune response.

Integrated Single-use Applicator

Vaxxas' HD-MAP coated with vaccine is integrated into single-use applicator, ready-for-vaccination. The product is designed to be effective and easy-to-use, while meeting industrial-scale manufacturing and commercial logistics requirements.

Compelling Benefits

Vaxxas HD-MAP vaccine products have clinically demonstrated a number of important benefits.

Robust immune response, dose sparing

Avoid cold chain complexity, easier distribution and storage

Increased accessibility, potential for self-administration

Enhance pandemic preparedness, faster response

Improve global health, increased vaccination rates

Clinical Validation

Vaxxas has validated its HD-MAP products in pre-clinical and human clinical settings. The company publishes results of its clinical studies in peer-reviewed publications; if you are interested in learning more about our clinical results, please contact us.